Antibe Therapeutics Inc.
ATBPF · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $10 | $10 |
| % Growth | – | -100% | 0.5% | – |
| Cost of Goods Sold | $0 | $0 | $6 | $6 |
| Gross Profit | $0 | -$0 | $4 | $4 |
| % Margin | – | – | 36.5% | 38.2% |
| R&D Expenses | $12 | $14 | $16 | $9 |
| G&A Expenses | $9 | $11 | $10 | $9 |
| SG&A Expenses | $9 | $11 | $10 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $4 |
| Other Operating Expenses | $0 | $0 | $0 | $2 |
| Operating Expenses | $21 | $26 | $24 | $22 |
| Operating Income | -$21 | -$26 | -$24 | -$19 |
| % Margin | – | – | -242.3% | -192.6% |
| Other Income/Exp. Net | $1 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$19 | -$25 | -$25 | -$19 |
| Tax Expense | $0 | -$0 | $2 | -$0 |
| Net Income | -$19 | -$25 | -$26 | -$19 |
| % Margin | – | – | -270.8% | -200.1% |
| EPS | -0.37 | -0.49 | -0.7 | -0.71 |
| % Growth | 24.5% | 30% | 1.4% | – |
| EPS Diluted | -0.37 | -0.49 | -0.7 | -0.71 |
| Weighted Avg Shares Out | 52 | 51 | 37 | 27 |
| Weighted Avg Shares Out Dil | 52 | 51 | 37 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$19 | -$25 | -$23 | -$18 |
| % Margin | – | – | -236.9% | -186% |